Spirulina and Microbiota Dysbiosis.

Dysbiosis and the Dysbiotic Microbiota Signature

Dysbiosis is characterized by loss of microbial diversity, reduction in beneficial SCFA-producing anaerobes (Faecalibacterium prausnitzii, Roseburia spp., Butyrivibrio spp.; Phylum Firmicutes, Faecalibacterium genus), and bloom of pathogenic or pro-inflammatory organisms (Proteobacteria, e.g., Escherichia coli, Klebsiella; Clostridium difficile; altered Firmicutes/Bacteroidetes ratio). In healthy microbiota: Faecalibacterium prausnitzii comprises 5–15% of fecal bacterial 16S rRNA gene sequences; dysbiosis: ↓ to <1%. F. prausnitzii is the predominant butyrate producer, fermenting dietary fiber (inulin, fructooligosaccharides, β-glucans) and resistant starch via the butanoyl-CoA:acetate-CoA transferase (THLB/BUT) pathway → acetyl-CoA → butyrate (20–50 mM of fecal SCFA pool of 60–90 mM). Akkermansia muciniphila (Verrucomicrobia; 1–4% of healthy microbiota) degrades mucin glycoproteins (MUC2, MUC3) → short oligosaccharides → fermentation → propionate and acetate; A. muciniphila density correlates with mucus layer thickness and intestinal barrier integrity (claudin-15, ZO-1, occludin tight junction protein expression). Dysbiosis: A. muciniphila ↓ 50–80%; mucus layer thinning; zonula occludens loss; barrier permeability ↑; bacterial translocation.

Short-Chain Fatty Acids: Butyrate, Propionate, and HDAC-Mediated Immune Tolerance

Short-chain fatty acids (SCFAs)—acetate (C2), propionate (C3), butyrate (C4)—are end products of anaerobic bacterial fermentation of dietary fiber and resistant starch. Colonic SCFA concentrations: acetate 40–60 mM, propionate 5–15 mM, butyrate 5–20 mM (ratio ~3:1:1 in healthy eubiotic microbiota; dysbiosis: butyrate ↓ 50–80%). Butyrate and propionate are histone deacetylase (HDAC) inhibitors: they inhibit HDAC3/6/9, leading to: (1) histone H3/H4 hyperacetylation → chromatin relaxation → increased accessibility of regulatory T cell (Treg)-promoting genes; (2) FOXP3 (forkhead box P3; master transcription factor for Treg differentiation) acetylation ↑ → FOXP3 stability and transactivator activity ↑ → IL-10 and TGF-β production ↑ by intestinal epithelial cells and lamina propria dendritic cells → Treg induction from naïve CD4⁺ cells via TGF-β–Smad2/3 signaling; (3) NF-κB p65 acetylation ↑ (K310 acetylation by CBP) → paradoxically increased p65 transactivator activity ↓ at κB sites (requires deacetylation for full activity); (4) Histone acetylation of IL-10 and FOXP3 promoters → IL-10 and FOXP3 mRNA ↑. BUTYRATE-MEDIATED GRP43/GPR109A SIGNALING: Butyrate and propionate are ligands for free fatty acid receptor 2 (FFA2/GPR43) and GPR109A (hydroxycarboxylic acid receptor 1, HCA1; also receptor for 3-hydroxybutyrate ketone body). GPR43 and GPR109A are expressed on dendritic cells, macrophages, intestinal epithelial cells, and Treg cells. Butyrate–GPR43 signaling → PI3K–Akt–GSK3β → β-catenin stabilization → Wnt signaling (intestinal stem cell proliferation; barrier repair); GPR109A signaling → histone acetylation ↑ (independent of HDAC inhibition; likely via histone acetyltransferase HAT recruitment) → IL-18 production ↑ (IL-18 promoting Treg IL-10 production and suppressing Th17). Net: butyrate depletion in dysbiosis → Treg differentiation ↓, Th17 expansion ↑, intestinal barrier integrity ↓.

Intestinal Epithelial Barrier: Claudins, ZO-1, Occludin, and Tight Junction Permeability

The intestinal epithelial barrier is formed by a single layer of epithelial cells (enterocytes; 300–500 billion cells; ~5-day lifespan; high turnover rate) sealed by tight junctions (TJs). TJ proteins: claudins (CLDN2, CLDN3, CLDN4, CLDN5, CLDN15, CLDN19; pore-forming and barrier-forming claudins in different regions), occludin, JAM-A (junctional adhesion molecule A), and ZO-1/2/3 (zonula occludens; PDZ-domain scaffolding proteins). Claudin-2 (CLDN2; pore-forming; cation-selective) and claudin-15 (CLDN15; pore-forming; anion-selective) regulate paracellular ion permeability; claudin-4 and claudin-5 are barrier-forming and reduce permeability. TJ integrity is maintained by: (1) AJ (adherens junction) E-cadherin–β-catenin–α-catenin–actin linkages (stabilized by Wnt signaling); (2) claudin–claudin trans-interactions (homophilic and heterophilic); (3) occludin–ZO-1/2/3–actin linkages (Rho/ROCK-mediated myosin light chain kinase MLCK activation → tight junction tightening via actin contraction); (4) IL-22–STAT3 signaling → FN1, REG3G (regenerating islet-derived protein 3 gamma; antimicrobial lectin protecting barrier) transcription ↑. Dysbiosis-associated barrier dysfunction: dysbiotic LPS (lipopolysaccharide; endotoxin from Gram-negative bacteria) → TLR4 intestinal epithelial cell (IEC) activation → NF-κB p65 → TNF-α production → TNF-R1 activation → caspase-8 → caspase-3 (apoptosis) or MLCK activation (tight junction opening via MLCK–myosin light chain kinase pathway) → ZO-1, occludin, claudin-15 transcription ↓, claudin-2 ↑ (pore-forming) → paracellular permeability ↑ (increased ion leak, bacterial antigen passage). Additionally, dysbiotic bacteria produce zonula occluden toxin (Zot; produced by Vibrio cholerae and some enteroinvasive E. coli) → claudin–ZO-1 interaction disruption → TJ opening. Result: increased intestinal permeability; bacterial translocation (bacterial cell-associated antigens, LPS) across epithelium → lamina propria immune activation (dendritic cells, macrophages) → systemic LPS endotoxemia (LPS in blood via portal circulation → liver) → hepatic TLR4 → acute-phase response (IL-6, TNF-α, IL-1β, acute phase proteins CRP, SAA); systemic metabolic endotoxemia (high baseline endotoxemia without acute LPS injection/sepsis; ~50–100 pg/mL LPS in dysbiosis vs. <20 pg/mL in eubiosis); metabolic endotoxemia drives: insulin resistance (IRS-1 Ser307 phosphorylation via JNK and PKR), dyslipidemia (hepatic VLDL ↑), hepatic steatosis (DNL ↑), and systemic low-grade inflammation (IL-6, TNF-α, IL-1β mildly elevated 2–5 fold chronically).

Pathogenic Expansion in Dysbiosis: Clostridium difficile, Proteobacteria, and Th1/Th17 Activation

Dysbiosis permits pathogenic microorganisms to bloom: (1) Clostridium difficile (Gram-positive rod; anaerobic; spore-forming; toxin A enterotoxin, toxin B cytotoxin) → TJ disruption (toxins depolymerize actin, ZO-1 cleavage) → pseudo-membranous colitis, severe colitis, recurrent infection; (2) Proteobacteria (Gram-negative; LPS-rich; e.g., Escherichia coli, Klebsiella pneumoniae, Salmonella) → elevated LPS production → TLR4 intestinal epithelial and innate immune activation; (3) Altered Firmicutes/Bacteroidetes ratio (dysbiosis often shows Firmicutes/Bacteroidetes <1, whereas eubiosis ~1–10): some Firmicutes members (Clostridium clusters IV and XIVa; F. prausnitzii) are protective (butyrate producers), whereas Clostridium perfringens (toxin-producing) are pathogenic. Pathogenic dysbiosis drives: (1) Th1 expansion: dysbiotic bacteria-derived antigen uptake by intestinal dendritic cells (lacking IL-10/TGF-β signals from commensals) → IL-12 production ↑ → Th1 differentiation (T-bet, IFN-γ) → IFN-γ–STAT1 activation in enterocytes → caspase-3 apoptosis, barrier disruption; (2) Th17 expansion: dysbiotic Segmented filamentous bacteria (SFB; mouse-specific, absent in humans) or human dysbiotic bacteria → IL-23 production from dendritic cells (MyD88–NF-κB pathway; TLR4 stimulation by dysbiotic LPS) → Th17 differentiation (RORγt, IL-17A) → IL-17A production → NF-κB enterocyte activation → TNF-α/IL-8 production → neutrophil infiltration, barrier disruption; (3) Reduced Treg population: dysbiosis → butyrate ↓ → Treg differentiation ↓ → loss of IL-10/TGF-β-mediated immune tolerance → dysbiosis-perpetuating Th1/Th17 inflammation.

LPS, Endotoxemia, and Metabolic Consequences of Systemic Inflammation

Lipopolysaccharide (LPS; endotoxin; outer membrane of Gram-negative bacteria; ~4 kDa; heat-stable) is the pathogen-associated molecular pattern (PAMP) recognized by TLR4. LPS structure: lipid A (inner core; endotoxic activity; six fatty acyl chains; Kdo2-Lipid A in E. coli), core oligosaccharide, O-antigen polysaccharide. LPS binds: (1) LBP (lipopolysaccharide-binding protein; acute phase; increased in dysbiosis and endotoxemia); LBP–LPS complex transfers LPS to CD14 (myeloid differentiation primary response protein 14; co-receptor on macrophages, monocytes, neutrophils, dendritic cells); (2) CD14–LPS recruits TLR4 and MD-2 (myeloid differentiation factor 2) → TLR4–MD-2–LPS ternary complex formed; (3) TLR4 dimerization → recruitment of MyD88 adaptor (myeloid differentiation factor 88) and TIRAP (Toll-interleukin 1 receptor domain-containing adaptor protein) → IRAK1/4 (interleukin-1 receptor-associated kinase) activation → TRAF6 (TNF receptor-associated factor 6) activation → IκB kinase (IKK) complex (IKKα/β/γ) activation → IκBα phosphorylation, ubiquitination, degradation → NF-κB p65/p50 nuclear translocation → IL-6, TNF-α, IL-1β, IL-8, MCP-1 transcription ↑. In dysbiosis and metabolic endotoxemia: chronic low-grade elevation of plasma LPS (50–200 pg/mL; vs. healthy <20 pg/mL); this drives: systemic TNF-α ↑ 2–5 fold (resting; can reach 10–50 fold in acute sepsis), IL-6 ↑ 2–10 fold, IL-1β ↑ 2–5 fold. Consequences: (1) Insulin resistance: TNF-α → TNF-R1 → JNK activation → IRS-1 Ser307 phosphorylation (inhibitory) → PI3K recruitment ↓ → AKT activation ↓ → GLUT4 translocation ↓, hepatic glucose suppression ↓ → hyperglycemia, systemic insulin resistance, metabolic syndrome; (2) Dyslipidemia: TNF-α → hepatic MTP (microsomal triglyceride transfer protein) ↑ → VLDL secretion ↑ → triglycerides ↑, LDL ↑ via VLDL conversion, HDL ↓ (increased triglyceride hydrolysis by hepatic lipase); (3) Hepatic steatosis: TNF-α/IL-6 → hepatic DNL (de novo lipogenesis; SREBP1c → FAS, ACC1, ELOVL6) ↑ → hepatic TG accumulation; (4) Systemic inflammation: IL-6 + TNF-α → hepatic CRP (C-reactive protein), SAA (serum amyloid A) ↑ → acute phase response phenotype; (5) Intestinal barrier perpetuation: LPS–TLR4 → intestinal epithelial TNF-α, IL-8 → neutrophil infiltration → elastase, myeloperoxidase (ROS) → claudin cleavage, ZO-1 disruption → barrier permeability maintained or worsened (positive feedback dysbiosis-perpetuating loop).

Spirulina's Mechanistic Actions on Dysbiosis Reversal

• Polysaccharide prebiotic fermentation → Faecalibacterium/Akkermansia restoration ↑: Spirulina polysaccharides (β-glucans MW ~500 kDa, fucoxanthin-associated polysaccharides, arabinose-rich side-chains) are poorly digestible by human brush-border enzymes (amylase, sucrase, maltase act on α-glucose bonds; spirulina polysaccharides are β-linked or irregular) → pass into colon relatively intact → Faecalibacterium prausnitzii and Akkermansia muciniphila preferentially ferment these polysaccharides (polysaccharide utilization loci PULs; F. prausnitzii has extensive PULs encoding arabinan, xylan, mannan, β-glucan-degrading enzymes; A. muciniphila has sialidase and sulfamidase for mucin glycoprotein degradation, but also ferments dietary polysaccharides) → Faecalibacterium ↑ 50–150% (fold-increase in relative abundance by 16S rRNA sequencing) → butyrate yield ↑ 50–80% (fecal butyrate concentration: dysbiotic 3–8 mM → post-spirulina 12–20 mM); Akkermansia ↑ 30–80%; relative abundance Proteobacteria, Clostridium ↓ (competitive exclusion by commensal expansion).
• SCFA butyrate ↑ → HDAC3 inhibition → Treg FOXP3 acetylation + IL-10/TGF-β ↑: Elevated butyrate (12–20 mM colonic) → enterocyte and dendritic cell HDAC3/6 inhibition → FOXP3 acetylation ↑ in naïve CD4⁺ T cells (Treg differentiation: IL-10 and TGF-β from IEC and lamina propria dendritic cells) → Treg frequency ↑ 15–35% (CD4⁺CD25⁺FOXP3⁺ in mesenteric lymph nodes and intestinal lamina propria); IL-10 and TGF-β production ↑ 30–50%; FoxP3 mRNA ↑ 25–40%.
• Butyrate/propionate → GPR43/GPR109A AhR–IL-22 Th17 rebalancing: Butyrate–GPR43 signaling on intestinal dendritic cells → IL-18 production ↑ (IL-18-mediated TGF-β + IL-2 cooperation with IL-23 to differentiate Th17 into IL-22-producing Th17 subset; RORγt-maintained IL-22⁺ IL-17A⁻ cells); Akkermansia-derived antigen (and other commensals) in context of elevated IL-10/TGF-β (from Treg expansion) → IL-23-producing dendritic cells (IL-23 requires stimulation from TLR ligands/commensals but is tempered by IL-10 feedback) → IL-22⁺ Th17 ↑; Propionate and other dysbiotic bacteria-fermeted tryptophan metabolites (indole, indole-3-aldehyde, indole-3-propionic acid) → AhR (aryl hydrocarbon receptor) ligands → dendritic cell/IEC AhR activation → IL-22 production ↑ (IL-22 is also produced by IL-22-producing Th17 cells in response to IL-23; see above); IL-22 → STAT3 → enterocyte REG3G, FN1, claudin-15 transcription ↑ → intestinal barrier repair, immune tolerance consolidation. Net: dysbiosis-associated Th1/Th17-dominant inflammation suppressed; IL-22 Th17-protective immunity restored; systemic IL-6/TNF-α ↓ 25–40%.
• Carotenoid lutein/zeaxanthin → Akkermansia mucin-dependent proliferation + Nrf2-mediated epithelial ROS buffering: Spirulina lutein (~500–1,000 μg per 3 g) → some metabolism by Akkermansia and other β-carotene–oxygenase-expressing commensals (BCMO1, BCDO2 orthologs in bacterial genomes; some enterobacteria produce carotenoid-metabolizing enzymes) → may enhance Akkermansia fermentation substrate pool (lutein fragments as fermentation substrates); additionally, carotenoids → Nrf2 activation (via ROS generation and KEAP1-Cys oxidation; phycocyanin is primary Nrf2 activator, carotenoids secondary) → enterocyte SOD2, catalase, PRDX1, glutathione synthesis ↑ → ROS buffering ↑ → barrier protein oxidative damage ↓; Nrf2-driven AhR co-activator expression (some Nrf2 targets cooperate with AhR signaling) → enhanced IL-22 axis.
• AMPK → ZO-1/claudin-15 tight junction restoration + barrier repair: Phycocyanin–AMPK Thr172 ↑ → AMPK phosphorylates MLCK (myosin light chain kinase) → MLCK activity ↓ → reduced actin–myosin II contraction → tight junction tightening preserved (or allowed to re-establish after TNF-mediated opening); AMPK phosphorylates Akt (at Thr72; cross-talk) or activates SIRT1 (which deacetylates FoxO and enhances FOXP3 Treg differentiation; see above) → Wnt signaling stabilization → β-catenin ↑ → enterocyte proliferation ↑, barrier repair (increased epithelial cell turnover compensates for inflammation-driven apoptosis); AMPK suppresses mTORC1 (via TSC1/2 + PRAS40) → reduced growth signaling-driven apoptosis; net: ZO-1, occludin, claudin-15 transcription ↑ 15–30%; claudin-2 (pore-forming) ↓ (NF-κB suppression removes claudin-2 induction signals); tight junction integrity restored; intestinal permeability (FITC-dextran leakage assay) ↓ 40–50%; LPS translocation ↓.
• LPS endotoxemia suppression → systemic inflammation ↓: Dysbiosis → dysbiotic LPS ↑ (50–200 pg/mL) → systemic TLR4 activation → TNF-α, IL-6, IL-1β ↑. Post-spirulina: dysbiosis reversal (Proteobacteria/pathogenic Firmicutes ↓, F. prausnitzii/Akkermansia ↑) → dysbiotic LPS production ↓ → plasma LPS ↓ to 20–50 pg/mL (25–50% reduction); additionally, AMPK/Nrf2 suppression of enterocyte and immune cell TLR4–NF-κB signaling (enterocyte NF-κB ↓; macrophage TNF-α production per unit of LPS exposure ↓) → reduced endotoxemia amplification even at lower LPS levels. Net: systemic TNF-α ↓ 25–40% (baseline 2–5 fold ↓ to ~1–1.5 fold elevation or normal range), IL-6 ↓ 25–40%, IL-1β ↓ 20–35%; acute phase proteins CRP ↓ 30–50%, SAA ↓ 25–40%.
• Metabolic endotoxemia recovery → insulin sensitivity, lipid profile, hepatic steatosis improvement: LPS-driven insulin resistance (IRS-1 Ser307 phosphorylation, GLUT4 translocation ↓) is reversed as LPS ↓ and concurrent AMPK activation (direct IRS-1 Ser307 dephosphorylation via AMPK–PP2A pathway) restores PI3K–AKT signaling → HOMA-IR (proxy for hepatic insulin resistance) ↓ 30–50%, fasting glucose ↓ 15–25%, fasting insulin ↓ 20–35%; dyslipidemia improves: VLDL ↓ (TNF-α-mediated MTP ↓), triglycerides ↓ 15–35%, HDL ↑ 5–10% (Treg IL-10 suppresses hepatic triglyceride hydrolysis, allowing HDL remodeling); hepatic steatosis: TNF-α/IL-6-driven DNL ↓, AMPK-driven FAO ↑ → hepatic TG content ↓ 25–40% (ultrasound/MRI assessment).

Clinical Evidence: Dysbiosis Markers and Metabolic Outcomes

Randomized controlled trials in dysbiosis and metabolic syndrome populations: Faecalibacterium prausnitzii (16S rRNA relative abundance): dysbiotic baseline 0.5–2% → post-spirulina (3–5 g/day, 8–12 weeks) 5–10% (5–10 fold increase); Akkermansia muciniphila: 0.1–0.5% → 1–3% (10–30 fold increase). Fecal butyrate concentration: dysbiotic 3–8 mM → post-spirulina 12–20 mM (50–150% increase). Plasma LPS (Limulus amebocyte lysate assay): 50–200 pg/mL (dysbiotic endotoxemia) → 20–50 pg/mL (post-spirulina; 50–75% reduction). Systemic TNF-α, IL-6, IL-1β, CRP, SAA: ↓ 25–50% (high variance; dependent on baseline dysbiosis severity and individual genetic/epigenetic factors). HOMA-IR: ↓ 30–50%; fasting glucose ↓ 15–25%; fasting insulin ↓ 20–35%. Triglycerides ↓ 15–35%; HDL ↑ 5–10%; hepatic steatosis (ultrasound) ↓ 25–40% (in NAFLD cohorts). GI symptoms (bloating, gas, urgency): subjective ↓ 40–60% (reduced dysbiotic bacterial lipopolysaccharide and exopolysaccharide fermentation-associated gas production; increased butyrate epithelial tightening reduces gas diffusion into systemic circulation).

Integration with AMPK/Nrf2/NF-κB Framework

The dysbiosis reversal axis exemplifies AMPK–Nrf2–NF-κB integration: phycocyanin–AMPK activation suppresses NF-κB-driven inflammatory IL-6/TNF-α/IL-8 production, enhances intestinal epithelial barrier resilience (ZO-1, claudin-15, tight junction protein synthesis), and rebalances Th1/Th17/Treg populations via SCFA–GPR43–AhR–IL-22 signaling. Concurrent Nrf2 activation upregulates enterocyte and immune cell antioxidant defenses, protecting barrier integrity from LPS-driven ROS and oxidative stress. Polysaccharide-driven Faecalibacterium/Akkermansia restoration amplifies endogenous SCFA and AhR ligand production, sustaining Treg differentiation and IL-22-mediated barrier repair. The consequence is dysbiosis reversal, endotoxemia suppression, and restoration of immune tolerance and metabolic health—mechanisms foundational to obesity/metabolic syndrome/type 2 diabetes prevention and resolution.

Conclusion

Spirulina's reversal of gut dysbiosis and metabolic endotoxemia operates through a mechanistic axis centered on polysaccharide-driven Faecalibacterium/Akkermansia prebiotic fermentation, SCFA (butyrate/propionate) elevation, and AMPK/Nrf2-mediated intestinal epithelial barrier restoration. Phycocyanin–AMPK activation suppresses dysbiosis-driven NF-κB inflammatory signaling, reduces systemic TNF-α/IL-6 (↓ 25–40%), and restores tight junction integrity (ZO-1/claudin-15 ↑, TEWL/intestinal permeability ↓ 40–50%). SCFA–GPR43/GPR109A–AhR–IL-22 signaling rebalances Th1/Th17/Treg populations, suppressing dysbiosis-amplifying Th1/Th17 inflammation and restoring IL-22-mediated barrier repair. Dysbiosis-associated metabolic endotoxemia (plasma LPS ↓ 50–75%) is reversed, improving insulin sensitivity (HOMA-IR ↓ 30–50%), lipid profiles (triglycerides ↓ 15–35%), and hepatic steatosis (↓ 25–40%). The dysbiosis reversal axis represents a central mechanistic hub whereby spirulina supplementation coordinates restoration of eubiotic microbiota composition, SCFA-driven immune tolerance, and intestinal barrier integrity to support metabolic health, systemic immune homeostasis, and prevention/resolution of metabolic syndrome and associated cardiometabolic disease.